Human hepatitis B Immunoglobulin (Hepatect®CP/ Zutectra®)
Protein / enzyme therapeutic
Evidence outlook
Approved: Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult... (EU)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also approved (1)
- Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start. The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ZEUS NCT01856413 · Chronic Hepatitis B Registry: NCT01856413 | 3 | Trough levels of serum anti-HBs antibody concentrations (24 weeks) 2014-09 | No treatment failures; mean anti-HBs declined to month 6 and plateaued at a protective titre of about 290 IU/L. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.